Glenmark Pharmaceuticals Ltd. (GLENMARK) fundamentals
Glenmark Pharmaceuticals Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as GLENMARK (ISIN INE935A01035). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Glenmark Pharmaceuticals Ltd. does
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Valuation and market data
| Last close | ₹2415.00 |
|---|---|
| Market capitalisation | ₹68,154 crore |
| Enterprise value | ₹69,999 crore |
| P/E (TTM) | 50.04 |
| Price to book | 6.48 |
| Price to sales (TTM) | 2.18 |
| Book value per share | ₹372.48 |
| Dividend yield | 31.06% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Feb 07 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹9,212 crore | ₹-266 crore | ₹-201 crore | -7.12 |
| Mar 2025 | ₹9,583 crore | ₹2,154 crore | ₹1,610 crore | 57.07 |
| Mar 2024 | ₹9,059 crore | ₹7,001 crore | ₹5,167 crore | 183.13 |
| Mar 2023 | ₹9,207 crore | ₹1,572 crore | ₹1,209 crore | 42.84 |
| Mar 2022 | ₹8,756 crore | ₹2,337 crore | ₹1,998 crore | 70.80 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 46.6% |
|---|---|
| Foreign institutions (FII) | 20.9% |
| Mutual funds | 16.8% |
| Other domestic institutions | 1.9% |
| Retail and others | 13.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.